Clinical trial
Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine…
NCT00291889 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00291889 |
|---|---|
| Title | Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults. |
| Official title | Evaluate the Safety, Reactogenicity & Immunogenicity of 2 Antigen Dose Levels of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02 to Healthy PPD-negative Volunteers Aged 18 to 45 Yrs |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tuberculosis (TB) |
| Intervention type | Biological |
| Interventions | Mtb72F/AS02. |
| Enrollment | 50 |
| Start date | Jul 1, 2004 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Feb 15, 2006 |
| Last update posted | May 30, 2017 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: